Audion Therapeutics is a private biopharmaceutical company dedicated to the discovery and development of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss. Audion’s headquarters are in Amsterdam, The Netherlands and our labs are in Cambridge, MA, USA.
Our mission is to improve the lives of patients suffering from the most prevalent forms of hearing. In 2015, almost 7% of the world’s population, approximately half a billion people, had disabling hearing loss. In 2015 hearing loss was the 4th leading cause of years lived with disability (YLDs). The reach of hearing loss extends far beyond sensory impairment in young as well as older people. Yet no drug treatments currently exist. We are committed to discovering effective therapies through our world-leading research into inner ear cellular biology and physiology. To achieve our goals we collaborate with leading research institutions and companies both in the EU and US.
Audion is coordinator of the REGAIN Project funded bij the European Union through the Horizon 2020 program. REGAIN started in 2015 to take a drug identified by Audion into clinical trials. Preclinical development was completed in 2017 and a positive clinical phase 1 study has been completed at the end of 2018 and the drug has been shown to be safe. Recruitment of patients for phase 2 has commenced in January 2019 in Tübingen, Athens and London.
Who can take part in the REGAIN study?
You may be eligible if:
- You are aged 18-80 years
- You have lived with the symptoms of hearing loss for less than 10 years
- You are using hearing aids or they have been previously offered to you
If you also suffer from tinnitus, and this is more of a problem to you than your hearing loss, you will not be eligible to take part.